{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T06:23:49Z","timestamp":1789885429904,"version":"4.0.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T00:00:00Z","timestamp":1559865600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T00:00:00Z","timestamp":1559865600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Fondazione I.R.C.C.S. Policlinico San Matteo"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s10238-019-00562-x","type":"journal-article","created":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T17:28:28Z","timestamp":1559928508000},"page":"367-375","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Functional polymorphisms of the receptor for the advanced glycation end product promoter gene in inflammatory bowel disease: a case\u2013control study"],"prefix":"10.1007","volume":"19","author":[{"given":"Rachele","family":"Ciccocioppo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Bozzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Betti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venerina","family":"Imbesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Klersy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia Sukovska","family":"Lakyova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Sukovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jozef","family":"Benacka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7069-3784","authenticated-orcid":false,"given":"Peter","family":"Kruzliak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gino Roberto","family":"Corazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Di Sabatino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colomba","family":"Falcone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,7]]},"reference":[{"key":"562_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrgastro.2015.186","volume":"13","author":"HSP de Souza","year":"2016","unstructured":"de Souza HSP, Fiocchi C. Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol. 2016;13:13\u201327.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"562_CR2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.tips.2016.10.014","volume":"38","author":"M Coskun","year":"2017","unstructured":"Coskun M, Vermeire S, Nielsen OH. Novel targeted therapies for inflammatory bowel disease. Trends Pharmacol Sci. 2017;38:127\u201342.","journal-title":"Trends Pharmacol Sci"},{"key":"562_CR3","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/nature11582","volume":"491","author":"L Jostins","year":"2012","unstructured":"Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119\u201324.","journal-title":"Nature"},{"key":"562_CR4","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/ng.3359","volume":"47","author":"JZ Liu","year":"2015","unstructured":"Liu JZ, van Sommeren S, Huang H, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet. 2015;47:979\u201386.","journal-title":"Nat Genet"},{"key":"562_CR5","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/gut.2009.206466","volume":"60","author":"T Fritz","year":"2011","unstructured":"Fritz T, Niederreiter L, Adolph T, Blumberg RS, Kaser A. Crohn\u2019s disease: NOD2, autophagy and ER stress converge. Gut. 2011;60:1580\u20138.","journal-title":"Gut"},{"key":"562_CR6","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/ibd.21868","volume":"18","author":"A Kabi","year":"2012","unstructured":"Kabi A, Nickerson KP, Homer CR, McDonald C. Digesting the genetics of inflammatory bowel disease: insights from studies of autophagy risk genes. Inflamm Bowel Dis. 2012;18:782\u201392.","journal-title":"Inflamm Bowel Dis"},{"key":"562_CR7","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1146\/annurev.immunol.021908.132603","volume":"28","author":"GP Sims","year":"2010","unstructured":"Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol. 2010;28:367\u201388.","journal-title":"Annu Rev Immunol"},{"key":"562_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0167-4889(00)00087-2","volume":"1498","author":"AM Schmidt","year":"2000","unstructured":"Schmidt AM, Yan SD, Yan SF, Stern DM. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta. 2000;1498:99\u2013111.","journal-title":"Biochim Biophys Acta"},{"key":"562_CR9","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1172\/JCI200114002","volume":"108","author":"AM Schmidt","year":"2001","unstructured":"Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Investig. 2001;108:949\u201355.","journal-title":"J Clin Investig"},{"key":"562_CR10","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1007\/s00109-005-0688-7","volume":"83","author":"A Bierhaus","year":"2005","unstructured":"Bierhaus A, Humpert PM, Morcos M, et al. Understanding RAGE: the receptor for advanced glycation end products. J Mol Med. 2005;83:876\u201386.","journal-title":"J Mol Med"},{"key":"562_CR11","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1136\/gut.52.6.847","volume":"52","author":"D Foell","year":"2003","unstructured":"Foell D, Kucharzik T, Kraft M, et al. Neutrophil derived human S100A12 (EN-RAGE) in strongly expressed during chronic active inflammatory bowel disease. Gut. 2003;52:847\u201353.","journal-title":"Gut"},{"key":"562_CR12","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1038\/ajg.2011.231","volume":"106","author":"R Vitali","year":"2011","unstructured":"Vitali R, Stronati L, Negroni A, et al. Fecal HMGB1 is a novel marker of intestinal mucosal inflammation in pediatric inflammatory bowel disease. Am J Gastroenterol. 2011;106:2029\u201340.","journal-title":"Am J Gastroenterol"},{"key":"562_CR13","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1189\/jlb.1008662","volume":"86","author":"SH Dav\u00e9","year":"2009","unstructured":"Dav\u00e9 SH, Tilstra JS, Matsuoka K, et al. Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis. J Leukoc Biol. 2009;86:633\u201343.","journal-title":"J Leukoc Biol"},{"key":"562_CR14","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1006\/geno.1994.1517","volume":"23","author":"K Sugaya","year":"1994","unstructured":"Sugaya K, Fukagawa T, Matsumoto K, et al. Three genes in the human MHC class III region near the junction with the class II: gene for receptor of advanced glycosylation end products, PBX2 homeobox gene and a notch homolog, human counterpart of mouse mammary tumor gene int-3. Genomics. 1994;23:408\u201319.","journal-title":"Genomics"},{"key":"562_CR15","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.2337\/diabetes.47.7.1155","volume":"47","author":"BI Hudson","year":"1998","unstructured":"Hudson BI, Stickland MH, Grant PJ. Identification of polymorphisms in the receptor for advanced glycation end products (RAGE) gene: prevalence in type 2 diabetes and ethnic groups. Diabetes. 1998;47:1155\u20137.","journal-title":"Diabetes"},{"key":"562_CR16","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.2337\/diabetes.50.6.1505","volume":"50","author":"B Hudson","year":"2001","unstructured":"Hudson B, Stickland MH, Futers S, Grant PJ. Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes. 2001;50:1505\u201311.","journal-title":"Diabetes"},{"key":"562_CR17","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s12031-009-9291-7","volume":"39","author":"Z Tiszlavicz","year":"2009","unstructured":"Tiszlavicz Z, Gyulai Z, Bencsik K, et al. RAGE gene polymorphisms in patients with multiple sclerosis. J Mol Neurosci. 2009;39:360\u20135.","journal-title":"J Mol Neurosci"},{"key":"562_CR18","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1177\/0961203312444495","volume":"21","author":"HA Martens","year":"2012","unstructured":"Martens HA, Nienhuis HL, Gross S, et al. Receptor for advanced glycation end products (RAGE) polymorphisms are associated with systemic lupus erythematosus and disease severity in lupus nephritis. Lupus. 2012;21:959\u201368.","journal-title":"Lupus"},{"key":"562_CR19","doi-asserted-by":"publisher","first-page":"G823","DOI":"10.1152\/ajpgi.00115.2010","volume":"300","author":"J D\u00e4britz","year":"2011","unstructured":"D\u00e4britz J, Friedrichs F, Weinhage T, et al. The functional -374T\/A polymorphism of the receptor for advanced glycation and products (RAGE) may modulate Crohn\u2019s Disease. Am J Physiol Gastrointest Liver Physiol. 2011;300:G823\u201332.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"562_CR20","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.imlet.2015.09.003","volume":"170","author":"J Wang","year":"2016","unstructured":"Wang J, Zeng J, Wang H, Ye S, et al. Genetic polymorphisms of RAGE and risk of ulcerative colitis in a Chinese population. Immunol Lett. 2016;170:88\u201394.","journal-title":"Immunol Lett"},{"key":"562_CR21","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","volume":"389","author":"J Torres","year":"2017","unstructured":"Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn\u2019s disease. Lancet. 2017;389:1741\u201355.","journal-title":"Lancet"},{"key":"562_CR22","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","volume":"389","author":"R Ungaro","year":"2017","unstructured":"Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389:1756\u201370.","journal-title":"Lancet"},{"key":"562_CR23","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1136\/gut.2005.082909","volume":"55","author":"J Satsangi","year":"2006","unstructured":"Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus and implications. Gut. 2006;55:749\u201353.","journal-title":"Gut"},{"key":"562_CR24","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/ecco-jcc\/jjv213","volume":"10","author":"M Harbord","year":"2016","unstructured":"Harbord M, Annese V, Vavricka SR, et al. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2016;10:239\u201354.","journal-title":"J Crohns Colitis"},{"key":"562_CR25","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","volume":"70","author":"WR Best","year":"1976","unstructured":"Best WR, Beckel JM, Singleton JW, Kern F Jr. Development of a Crohn\u2019s disease activity index: national cooperative Crohn\u2019s disease study. Gastroenterology. 1976;70:439\u201344.","journal-title":"Gastroenterology"},{"key":"562_CR26","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1136\/bmj.298.6666.82","volume":"298","author":"D Rachmilewitz","year":"1989","unstructured":"Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomized trial. Br Med J. 1989;298:82\u20136.","journal-title":"Br Med J"},{"key":"562_CR27","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.1371\/journal.pmed.1000022","volume":"6","author":"J Little","year":"2009","unstructured":"Little J, Higgins JPT, Ioannidis JPA, et al. Strengthening the Reporting of Genetic Association Studies (STREGA): an extension of the STROBE statement. Plos Med. 2009;6:e22.","journal-title":"Plos Med"},{"key":"562_CR28","first-page":"287","volume":"44","author":"P Munkholm","year":"1997","unstructured":"Munkholm P. Crohn\u2019s disease: occurrence, course and prognosis. An epidemiologic cohort-study. Dan Med Bull. 1997;44:287\u2013302.","journal-title":"Dan Med Bull"},{"key":"562_CR29","doi-asserted-by":"publisher","first-page":"260","DOI":"10.3109\/00365529609004876","volume":"31","author":"E Langholz","year":"1996","unstructured":"Langholz E, Munkholm P, Davidsen M, Nielsen OH, Binder V. Changes in extent of ulcerative colitis: a study on the course and prognostic factors. Scand J Gastroenterol. 1996;31:260\u20136.","journal-title":"Scand J Gastroenterol"},{"key":"562_CR30","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.2353\/ajpath.2006.050713","volume":"169","author":"M Andrassy","year":"2006","unstructured":"Andrassy M, Igwe J, Autschbach F, et al. Posttranslationally modified proteins as mediators of sustained intestinal inflammation. Am J Pathol. 2006;169:1223\u201337.","journal-title":"Am J Pathol"},{"key":"562_CR31","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.crohns.2011.03.011","volume":"5","author":"Y Yilmaz","year":"2011","unstructured":"Yilmaz Y, Yonal O, Eren F, Atug O, Hamzaoglu HO. Serum levels of soluble receptor for advanced glycation and products (sRAGE) are higher in ulcerative colitis and correlate with disease activity. J Chrons Colitis. 2011;5:402\u20136.","journal-title":"J Chrons Colitis"},{"key":"562_CR32","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.arcmed.2007.11.003","volume":"39","author":"C Falcone","year":"2008","unstructured":"Falcone C, Geroldi D, Buzzi MP, et al. The -374T\/A RAGE polymorphism protects against future cardiac events in nondiabetic patients with coronary artery disease. Arch Med Res. 2008;39:320\u20135.","journal-title":"Arch Med Res"},{"key":"562_CR33","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1515\/CCLM.2007.273","volume":"45","author":"G Picheth","year":"2007","unstructured":"Picheth G, Costantini CO, Pedrosa FO, da Rocha Leme, Martinez T, Maltempi de Souza E. The -374A allele of the receptor for advanced glycation end products (RAGE) gene promoter is a protective factor against cardiovascular lesions in type 2 diabetes mellitus patients. Clin Chem Lab Med. 2007;45:1268\u201372.","journal-title":"Clin Chem Lab Med"},{"key":"562_CR34","doi-asserted-by":"publisher","first-page":"823085","DOI":"10.1155\/2012\/823085","volume":"2012","author":"A Alunno","year":"2012","unstructured":"Alunno A, Bartoloni E, Bistoni O, et al. Balance between regulatory T and Th17 cells in systemic lupus erythematosus: the old and the new. Clin Dev Immunol. 2012;2012:823085.","journal-title":"Clin Dev Immunol"},{"key":"562_CR35","doi-asserted-by":"publisher","first-page":"e41913","DOI":"10.1371\/journal.pone.0041913","volume":"7","author":"J Beucher","year":"2012","unstructured":"Beucher J, Bo\u00eblle PY, Busson PF, Modifier Gene Study Investigators, et al. RAGE -429T\/C is associated with an increased lung disease severity in cystic fibrosis. Plos One. 2012;7:e41913.","journal-title":"Plos One"},{"key":"562_CR36","doi-asserted-by":"publisher","DOI":"10.2174\/0929867325666180904115633","author":"FA Moura","year":"2018","unstructured":"Moura FA, Goulart MOF, da Paz Martins AS, Campos SBG. Close interplay of nitro-oxidative stress, advanced glycation end products and inflammation in inflammatory bowel diseases. Curr Med Chem. 2018. \n                    https:\/\/doi.org\/10.2174\/0929867325666180904115633\n                    \n                  .","journal-title":"Curr Med Chem"},{"key":"562_CR37","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1136\/gutjnl-2014-307118","volume":"64","author":"G D\u2019Haens","year":"2015","unstructured":"D\u2019Haens G, Sandborn WJ, Colombel JF, et al. A phase II study of laquinimod in Crohn\u2019s\u00a0disease. Gut. 2015;64:1227\u201335.","journal-title":"Gut"},{"key":"562_CR38","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/s41385-018-0119-z","volume":"12","author":"M Body-Malapel","year":"2019","unstructured":"Body-Malapel M, Djouina M, Waxin C, et al. The RAGE signaling pathway is involved in intestinal inflammation and represents a promising therapeutic target for inflammatory bowel diseases. Mucosal Immunol. 2019;12:468\u201378.","journal-title":"Mucosal Immunol"},{"key":"562_CR39","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/gut.2010.224154","volume":"60","author":"C Mowat","year":"2011","unstructured":"Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60:571\u2013607.","journal-title":"Gut"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-019-00562-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10238-019-00562-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-019-00562-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T23:15:29Z","timestamp":1591398929000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10238-019-00562-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,7]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["562"],"URL":"https:\/\/doi.org\/10.1007\/s10238-019-00562-x","relation":{},"ISSN":["1591-8890","1591-9528"],"issn-type":[{"value":"1591-8890","type":"print"},{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,7]]},"assertion":[{"value":"27 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Ciccocioppo received a consulting (honorary) fee by Takeda Pharmaceuticals, and she is a member of the Advisory Board Takeda Italy. All the other authors of this manuscript have no conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}